Treatment of Priapism Secondary to Drugs for Erectile Dysfunction
Priapism may present as a side effect in patients treated with medications for erectile dysfunction, in which it should be controlled in a timely manner to avoid complications. There is little information regarding the use of local measures for the treatment of this condition. This study was done wi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2019/6214921 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550664358592512 |
|---|---|
| author | José Pablo Saffon Cuartas Carolina Sandoval-Salinas Juan M. Martínez Héctor A. Corredor |
| author_facet | José Pablo Saffon Cuartas Carolina Sandoval-Salinas Juan M. Martínez Héctor A. Corredor |
| author_sort | José Pablo Saffon Cuartas |
| collection | DOAJ |
| description | Priapism may present as a side effect in patients treated with medications for erectile dysfunction, in which it should be controlled in a timely manner to avoid complications. There is little information regarding the use of local measures for the treatment of this condition. This study was done with the objective to describe the management of priapism secondary to erectile dysfunction drugs in a cohort of men. Records of emergencies and adverse events were reviewed by two researchers to identify patients diagnosed with erectile dysfunction who received oral or intracavernosal drugs for their illness and presented priapism. Sociodemographic data, clinical background, and information on the duration, management, and evolution of the priapism were extracted. Priapism incidence, percentage of improvement by type of treatment subgroups, and frequency of complications were estimated. 698 patients were treated with PDE-5 inhibitors and 2,135 with intracavernosal drugs. Thirty-one patients (1.4%) reported at least one priapism event during treatment, all with intracavernosal drugs. Treatment with local measures was effective for 10 (32.2%) patients, 1 (3.2%) required terbutaline, 19 (61.2%) used intracavernosal etilefrine, and 1 (3.2%) required drainage and flushing of cavernous bodies. After the priapism episode, 3 (9.6%) patients required an increased dose of the drug in order to achieve satisfactory erection. The results suggest that in men treated for priapism secondary to the use of sexual impotence drugs, initial treatment with local measures and etilefrine can achieve detumescence, decreasing the need for invasive procedures or surgery as a first-line therapy alternative. It is necessary to carry out research studies to confirm this hypothesis. |
| format | Article |
| id | doaj-art-e86abdf1a45d48838aeec2c2eed33266 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-e86abdf1a45d48838aeec2c2eed332662025-02-03T06:06:16ZengWileyAdvances in Urology1687-63691687-63772019-01-01201910.1155/2019/62149216214921Treatment of Priapism Secondary to Drugs for Erectile DysfunctionJosé Pablo Saffon Cuartas0Carolina Sandoval-Salinas1Juan M. Martínez2Héctor A. Corredor3Clinical Research Group, Boston Medical Group, Bogotá 110111, ColombiaClinical Research Group, Boston Medical Group, Bogotá 110111, ColombiaClinical Research Group, Boston Medical Group, Bogotá 110111, ColombiaClinical Research Group, Boston Medical Group, Bogotá 110111, ColombiaPriapism may present as a side effect in patients treated with medications for erectile dysfunction, in which it should be controlled in a timely manner to avoid complications. There is little information regarding the use of local measures for the treatment of this condition. This study was done with the objective to describe the management of priapism secondary to erectile dysfunction drugs in a cohort of men. Records of emergencies and adverse events were reviewed by two researchers to identify patients diagnosed with erectile dysfunction who received oral or intracavernosal drugs for their illness and presented priapism. Sociodemographic data, clinical background, and information on the duration, management, and evolution of the priapism were extracted. Priapism incidence, percentage of improvement by type of treatment subgroups, and frequency of complications were estimated. 698 patients were treated with PDE-5 inhibitors and 2,135 with intracavernosal drugs. Thirty-one patients (1.4%) reported at least one priapism event during treatment, all with intracavernosal drugs. Treatment with local measures was effective for 10 (32.2%) patients, 1 (3.2%) required terbutaline, 19 (61.2%) used intracavernosal etilefrine, and 1 (3.2%) required drainage and flushing of cavernous bodies. After the priapism episode, 3 (9.6%) patients required an increased dose of the drug in order to achieve satisfactory erection. The results suggest that in men treated for priapism secondary to the use of sexual impotence drugs, initial treatment with local measures and etilefrine can achieve detumescence, decreasing the need for invasive procedures or surgery as a first-line therapy alternative. It is necessary to carry out research studies to confirm this hypothesis.http://dx.doi.org/10.1155/2019/6214921 |
| spellingShingle | José Pablo Saffon Cuartas Carolina Sandoval-Salinas Juan M. Martínez Héctor A. Corredor Treatment of Priapism Secondary to Drugs for Erectile Dysfunction Advances in Urology |
| title | Treatment of Priapism Secondary to Drugs for Erectile Dysfunction |
| title_full | Treatment of Priapism Secondary to Drugs for Erectile Dysfunction |
| title_fullStr | Treatment of Priapism Secondary to Drugs for Erectile Dysfunction |
| title_full_unstemmed | Treatment of Priapism Secondary to Drugs for Erectile Dysfunction |
| title_short | Treatment of Priapism Secondary to Drugs for Erectile Dysfunction |
| title_sort | treatment of priapism secondary to drugs for erectile dysfunction |
| url | http://dx.doi.org/10.1155/2019/6214921 |
| work_keys_str_mv | AT josepablosaffoncuartas treatmentofpriapismsecondarytodrugsforerectiledysfunction AT carolinasandovalsalinas treatmentofpriapismsecondarytodrugsforerectiledysfunction AT juanmmartinez treatmentofpriapismsecondarytodrugsforerectiledysfunction AT hectoracorredor treatmentofpriapismsecondarytodrugsforerectiledysfunction |